PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and efficacy of a novel tyrosine kinase inhibitor,
PTK787/ZK222584, in the treatment of GIST (gastrointestinal stromal tumor) that is resistant
to imatinib mesylate (Gleevec). The study participants are required to have histologically
confirmed GIST with prior imatinib treatment for metastatic GIST. is administered orally 1250
mg/day. Six patients will first enter the study. If clinical benefit is obtained in >1 of 6
patients, 9 and 30 additional patients will be entered into the protocol in two stages (a
maximum of 45 patients will be entered). Patients who benefit from the study treatment will
be treated with PTK787/ZK222584 until treatment failure.